等温核酸増幅技術の世界市場：市場規模・シェア分析 (製品別・技術別・用途別・エンドユーザー別)、産業成長の予測 (～2030年)

市場概要

世界の等温核酸増幅技術 (INAAT) 市場は、2023年に44億2,550万米ドルの収益を上げ、2024～2030年のCAGRは9.4%で、2030年には81億5,940万米ドルに達すると予測されています。この成長は、特に発展途上国における主な死因の一つである結核・肝炎・インフルエンザを含む感染症の有病率の上昇により、分子検査技術としての利用が大幅に増加したことに起因しています。

主な洞察

2023年には、消耗品カテゴリーが等温核酸増幅技術業界をリードし、70%の収益シェアを占め、優位性を維持すると予測されます。診断ラボや主要ヘルスケア環境での試薬の幅広い使用が、この優位性に寄与しています。

装置カテゴリーは、COVID-19のような感染症の新規診断技術への研究開発投資の増加により、最も速い成長を示すと予想されます。

2023年、病院のカテゴリーはINAAT業界で60%のシェアを占め、小型化されたPOC機器の使用増加により優位性を維持すると予測されます。

診断センターは、感染症緩和のための公的機関からの資金援助に支えられ、患者数の増加と早期疾患検出のための分子技術の採用により、最も高いCAGRを予測しています。

北米は2023年に市場の約45%を占め、確立された研究インフラと核酸増幅ベースの診断薬への需要により、堅調な成長が見込まれます。一人当たりの医療費の高さや、ポイントオブケア診断薬への関心が北米市場の拡大を牽引しています。

2023年には、ループ媒介増幅法がINAAT業界の40%の売上シェアを占め、今後も優位性を維持すると予測されています。LAMP技術のアップグレードにより、等温条件下で非常に指示性が高く、生産性が高く、高速なin-situ DNA製造プロセスが可能になります。

当レポートでは、世界の等温核酸増幅技術の市場について分析し、市場の基本構造・最新情勢や主な促進・抑制要因、世界全体および地域別・主要国の市場規模の動向見通し (金額ベース、2017～2030年)、製品別・技術別・用途別・エンドユーザー別の詳細動向、現在の市場競争の状況、主要企業のプロファイルなどを調査しております。

目次

第1章 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場指標

第5章 業界の展望

• 市場力学
  • 動向
  • 促進要因
  • 抑制要因/課題
  • 促進要因/抑制要因の影響分析
• 新型コロナウイルス感染症 (COVID-19) の影響
• ポーターのファイブフォース分析

第6章 世界市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：地域別 (2017～2030年)

第7章 北米市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)
• 市場収益：国別 (2017～2030年)

第8章 欧州市場

第9章 アジア太平洋市場

第10章 ラテンアメリカ市場

第11章 中東・アフリカ市場

第12章 米国市場

• 概要
• 市場収益：製品別 (2017～2030年)
• 市場収益：技術別 (2017～2030年)
• 市場収益：用途別 (2017～2030年)
• 市場収益：エンドユーザー別 (2017～2030年)

第13章 カナダ市場

第14章 ドイツ市場

第15章 フランス市場

第16章 英国市場

第17章 イタリア市場

第18章 スペイン市場

第19章 日本市場

第20章 中国市場

第21章 インド市場

第22章 オーストラリア市場

第23章 韓国市場

第24章 ブラジル市場

第25章 メキシコ市場

第26章 サウジアラビア市場

第27章 南アフリカ市場

第28章 アラブ首長国連邦 (UAE) 市場

第29章 競合情勢

• 市場参入企業とその提供品目の一覧
• 主要企業の競合ベンチマーク
• 主要企業の製品ベンチマーク
• 最近の戦略的展開

第30章 企業プロファイル

• Becton, Dickinson and Company
• QIAGEN N.V.
• Quidel Corporation
• bioMerieux SA
• Abbott Laboratories
• Meridian Bioscience Inc.
• Thermo Fisher Scientific Inc.
• Atila Biosystems
• Grifols S.A.
• Eiken Chemical Co. Ltd.

第31章 付録

Market Overview

The global isothermal nucleic acid amplification technology market generated revenue of USD 4,425.5 million in 2023 and is expected to witness a CAGR of 9.4% during 2024-2030, reaching USD 8,159.4 million by 2030. This growth is attributed to the significant increase in its usage as a molecular testing technique due to the rising prevalence of infectious diseases, including tuberculosis, hepatitis, and influenza, which are among the leading causes of death, particularly in developing countries.

Tuberculosis, hepatitis, and flu are diseases transmitted by way of infectious diseases in which the leading cause of death is mostly observed in underdeveloped countries.

a bewildering range of diagnostic tests combined with an increasing number of Emergency Use Authorizations for CLIA-waived tests are spurring the development of the isothermal nucleic acid amplification technology market. These tests being free of complex procedures, lesser chances of error, and being able to personalize the dose on patients are a few instances of why these tests remain so popular.

These technologies have various uses such as gene manipulation that is done with recombinant DNA and similar molecular biology practices. It is a new way to detect prepare and analyze a small number of nucleic acids containing DNA or RNA that enter into cells.

Historically, there has never been a life history that was free from infectious diseases and this has continued to be a major cause of death and disability. With the increasing incidences of communicable diseases around the world which as weighty factors in the market expansion, this field is seeing major growth nowadays.

Key Insights

In 2023, the consumables category led the isothermal nucleic acid amplification technology industry, with a 70% revenue share, projected to uphold supremacy.

The wide use of reagents in diagnostic laboratories and major healthcare settings contributes to this supremacy.

Obtainability of polymerases with high strand displacement abilities further boosts demand for consumables.

Companies are making numerous reagents to sense communicable diseases, confronting the growing occurrence.

Increasing cases of cardiovascular illnesses, diabetes, and cholesterol-linked illnesses drive the growth of convenient POC diagnostic devices.

The instruments category is expected to show the fastest growth due to increased R&D investments in novel diagnostic techniques for infectious diseases like COVID-19.

In 2023, the hospital's category led with a 60% share in the INAAT industry, projected to uphold supremacy because of the augmented usage of miniaturized POC instruments.

Increased throughput and automation capabilities of INAAT technologies for processing large sample volumes are expected to drive segment growth.

Diagnostic centers forecast the highest CAGR due to rising numbers and the adoption of molecular techniques for early disease detection, supported by funding from public agencies for infectious disease mitigation.

North America held around 45% of the market in 2023, poised for robust growth due to established research infrastructure and demand for nucleic-acid-amplification-based diagnostics.

High per capita healthcare spending and interest in point-of-care diagnostics drive market expansion in North America.

In 2023, loop-mediated amplification dominated the INAAT industry with a 40% revenue share, projected to uphold supremacy.

LAMP technology upgrades allow highly directive, productive, and fast in-situ DNA manufacturing process under isothermal conditions.

There recruitation of DNA polymerase and four primer adds protrusion of six different motifs on target DNA in DNA replication.

The kit is a microbial identification method which includes three types of detection techniques (lateral flow, agarose gel detection, and real-time fluorescence with intercalators)

LAMP against PCR's resistance to interactive molecules is that samples can be used even in the less purified form.

It has a potential for testing all RNA and DNA sequences at the same time and is capable of detecting both Zika and SARS-CoV-2 viruses in human specimens.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by product
  • 1.4.2. Market size breakdown, by technology
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Product (2017-2030)
• 6.3. Market Revenue, by Technology (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Product (2017-2030)
• 7.3. Market Revenue, by Technology (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Product (2017-2030)
• 8.3. Market Revenue, by Technology (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Product (2017-2030)
• 9.3. Market Revenue, by Technology (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Product (2017-2030)
• 10.3. Market Revenue, by Technology (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Product (2017-2030)
• 11.3. Market Revenue, by Technology (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Product (2017-2030)
• 12.3. Market Revenue, by Technology (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Product (2017-2030)
• 13.3. Market Revenue, by Technology (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Product (2017-2030)
• 14.3. Market Revenue, by Technology (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Product (2017-2030)
• 15.3. Market Revenue, by Technology (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Product (2017-2030)
• 16.3. Market Revenue, by Technology (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Product (2017-2030)
• 17.3. Market Revenue, by Technology (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Product (2017-2030)
• 18.3. Market Revenue, by Technology (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Product (2017-2030)
• 19.3. Market Revenue, by Technology (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Product (2017-2030)
• 20.3. Market Revenue, by Technology (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Product (2017-2030)
• 21.3. Market Revenue, by Technology (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Product (2017-2030)
• 22.3. Market Revenue, by Technology (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Product (2017-2030)
• 23.3. Market Revenue, by Technology (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Product (2017-2030)
• 24.3. Market Revenue, by Technology (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Product (2017-2030)
• 25.3. Market Revenue, by Technology (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Product (2017-2030)
• 26.3. Market Revenue, by Technology (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Product (2017-2030)
• 27.3. Market Revenue, by Technology (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Product (2017-2030)
• 28.3. Market Revenue, by Technology (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Becton, Dickinson and Company
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. QIAGEN N.V.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Quidel Corporation
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. bioMerieux SA
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Abbott Laboratories
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Meridian Bioscience Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Thermo Fisher Scientific Inc.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Atila Biosystems
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Grifols S.A.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Eiken Chemical Co. Ltd.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports